News
CardioGenics Holdings Inc. Receives New Ticker Symbol
Mississauga, Ontario, July 22, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's ticker symbol has been changed back to "CGNH" and the Company's common stock began trading under that new symbol yesterday.
read more
CardioGenics And Merck In Second Product Agreement
Mississauga, Ontario, July 14, 2010 - CardioGenics Holdings Inc. (OTCBB: CGNHD), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company‘s subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.
read more
CardioGenics Holdings Inc. Announces Initial Members of Scientific Advisory Board
Mississauga, Ontario, June 29, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNHD), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that Professors Robert Roberts and William J. Kostuk are the first two members to join the Company's Scientific Advisory Board. Biographical information for Drs. Roberts and Kostuk is detailed below.
read more
CardioGenics Holdings Inc. Receives New Ticker Symbol as a Result of Reverse Stock Split (OTCBB: CGNHD)
Mississauga, Ontario, June 21, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company has been assigned a new ticker symbol by FINRA as a result of its recently announced share consolidation. The new ticker symbol is OTCBB: CGNHD and the Company has been informed by FINRA that its common stock will begin trading under that symbol commencing tomorrow the 22nd of June 2010 when the share consolidation becomes effective in the market. The "D" in the new ticker symbol will be removed by FINRA 20 business days after tomorrow.
read more
CardioGenics Selects Clinical Test Sites For Its High Speed Portable Blood Analyzer
Mississauga, Ontario, June 21, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced the selection of four sites for clinical testing of its patented QL Care™ Analyzer, a portable diagnostic platform designed to produce test results with central lab-like accuracy in 15 minutes using whole blood.
read more
New Corporate Profile Posted On CardioGenics' Website
Mississauga, Ontario, June 18, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced a new corporate profile is available at
http://www.cardiogenics.com/ataglance/ataglance.pdf
read more
CardioGenics Announces Reverse Stock Split
Mississauga, Ontario, June 18, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today that the Company has filed a Certificate of Change with the Secretary of State of Nevada, which implements a share consolidation of the Company's authorized and outstanding common stock on a ten (old) for one (new) basis.
read more
CardioGenics Spotlighted in May Issue of Medical Tourism Magazine
Mississauga, Ontario, May 28, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, is spotlighted in the May issue of Medical Tourism Magazine in an article written by CardioGenics founder and CEO Yahia Gawad, MD.
read more
CardioGenics Announces Update Regarding Status of Merck Agreement
Mississauga, Ontario, May 27, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, announced today a further update regarding the status of its agreement with Merck Chimie S.A.S. ("Merck Chimie"), one of the largest manufacturers and distributors of magnetic beads for the diagnostics market.
read more
CardioGenics Announces Retention of Redington, Inc. to Provide Investor Relations Services for the Company
Mississauga, Ontario, May 20, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Redington, Inc. to provide investor relations and financial communications services for the Company.
read more
CardioGenics to be Spotlighted in Three Publications During Month of April
Mississauga, Ontario, April 22, 2010 - CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, will be spotlighted in three publications during the month of April: Today's Medical Developments, Medical Design Technology and The Wall Street Transcript
read more
CardioGenics Announces Lock-Up Agreements with Board Members, Executives and Certain Other Stockholders
Mississauga, Ontario, March 25, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the Point-Of-Care (POC) segment of the IVD market announced today that the Company has entered into lock-up agreements with its directors (other than Dr. Yahia Gawad who previously entered into a lock-up agreement with the Company) pursuant to which the directors agreed to lock-up 38,759,113 shares of the Company's common stock held directly and indirectly by the directors through "Exchangeable Shares" in the Company's wholly-owned Ontario, Canada subsidiary, CardioGenics ExchangeCo Inc. ("ExchangeCo"). ExchangeCo and WeirFoulds LLP (as "trustee" under that certain Voting and Exchange Trust Agreement dated July 6, 2009 among the Company, ExchangeCo and WeirFoulds LLP) are also parties to these lock-up agreements.
read more
CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
Mississauga, Ontario, March 16, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the Point-Of-Care (POC) segment of the IVD market announced today that the Company has entered into a lock-up agreement with its chief executive officer, Dr. Yahia Gawad, pursuant to which Dr. Gawad has agreed to lock-up 150,000,000 million shares of the Company's common stock held indirectly by Dr. Gawad through "Exchangeable Shares" in the Company's wholly-owned Ontario, Canada subsidiary, CardioGenics ExchangeCo Inc. ("ExchangeCo"). ExchangeCo and WeirFoulds LLP, as "trustee" under that certain Voting and Exchange Trust Agreement dated July 6, 2009 among the Company, ExchangeCo and WeirFoulds LLP, are also parties to the lock-up agreement.
read more
CardioGenics Announces Further Update Regarding Status of Merck Agreement
Mississauga, Ontario, March 10, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market,announced today a further update regarding the status of its agreement with Merck Chimie s.a.s. ("Merck Chimie").
read more
CardioGenics Holdings Inc. Announces Completion of Cartridge Design for QL Care Analyzer
Mississauga, Ontario, January 27, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, announced today that it has completed the design of the self-metering cartridge for its POC diagnostic device, the QL Care Analyzer.The company has also filed a patent application regarding the self-metering cartridge.
read more
CardioGenics Announces Retention of Wolfe Axelrod Weinberger Associates LLC to Provide Investor Relations Services for the Company
Mississauga, Ontario, January 20, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Wolfe Axelrod Weinberger Associates LLC to provide investor relations services for the Company. Effective January 18, 2010, all shareholder inquires should be directed to:
Wolfe Axelrod Weinberger Associates LLC
Tel: 1.212.370.4500
E-Mail: rob@wolfeaxelrod.com
read more
Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
Mississauga, Ontario, December 30, 2009 - Dr. Yahia Gawad, Chief Executive Officer of CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was interviewed in MedTech Executive. The article touches on the technical and market environment for developing its QL Care Analyzer device, the FDA approval process, InVitro Diagnostic (IVD) trends, and the investment climate for immunoassay products following CardioGenics' recent business agreement with Merck Chimie, S.A.S. To read the article in full, please visit http://www.devicelink.com/mx/issuesupdate/09/12/gawad.html
read more
CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
Mississauga, Ontario, November 24,2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, reports that Merck Chimie S.A.S. ("Merck Chimie") is progressing to the next phase of the commercialization of CardioGenics' proprietary silver coated paramagnetic Beads ("Beads").
read more
CardioGenics Holdings Inc. Featured in Medical Device Daily
Mississauga, Ontario, November 13, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was featured in Medical Device Daily's November 12, 2009 edition.
read more
CardioGenics Holdings Inc. Announces Letter To Shareholders
Mississauga, Ontario, October 27, 2009 - CardioGenics Holdings Inc. (OTCBB: CGNH), a developer of technology and products targeting the immunoassay segment of the In-Vitro Diagnostic (IVD) testing market, has issued a letter to its shareholders. To view the letter in its entirety, please visit the following link: http://irgnews.com/node/1633.
read more
CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change.
Mississauga, Ontario, October 26, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has received notification from FINRA that the name and ticker symbol change for the Company on the OTCBB will take place at the beginning of business on Tuesday, October 27, 2009.
read more
Company Name Changed to CardioGenics Holdings Inc.
Mississauga, Ontario, October 2, 2009 - JAG Media Holdings, Inc. (OTCBB: JAGH) filed with the Secretary of State of Nevada yesterday a certificate of amendment to its Articles of Incorporation, which changed the Company's name to CardioGenics Holdings Inc., to better reflect its new business direction following its acquisition of CardioGenics Inc., and increased the Company's authorized common shares from 500,000,000 to 650,000,000.
read more
JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.
Mississauga, Ontario, September 11, 2009 - JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) has entered into an agreement with The Investor Relations Group, Inc. ("IRG"), pursuant to which IRG will provide various investor relations and public relations services for the Company in accordance with the terms of the agreement. As of Tuesday, September 15th, all stockholders should address any inquiries directly to IRG.
read more
